Logo image of CRMD

CORMEDIX INC (CRMD) Stock Fundamental Analysis

NASDAQ:CRMD - Nasdaq - US21900C3088 - Common Stock - Currency: USD

9.19  +0.07 (+0.77%)

After market: 9.19 0 (0%)

Fundamental Rating

4

Taking everything into account, CRMD scores 4 out of 10 in our fundamental rating. CRMD was compared to 198 industry peers in the Pharmaceuticals industry. No worries on liquidiy or solvency for CRMD as it has an excellent financial health rating, but there are worries on the profitability. CRMD is not valued too expensively and it also shows a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year CRMD has reported negative net income.
CRMD had a negative operating cash flow in the past year.
CRMD had negative earnings in each of the past 5 years.
CRMD had a negative operating cash flow in each of the past 5 years.
CRMD Yearly Net Income VS EBIT VS OCF VS FCFCRMD Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M -40M -50M

1.2 Ratios

Looking at the Return On Assets, with a value of -15.09%, CRMD is in the better half of the industry, outperforming 67.17% of the companies in the same industry.
Looking at the Return On Equity, with a value of -21.18%, CRMD is in the better half of the industry, outperforming 70.71% of the companies in the same industry.
Industry RankSector Rank
ROA -15.09%
ROE -21.18%
ROIC N/A
ROA(3y)-39.81%
ROA(5y)-41%
ROE(3y)-47.06%
ROE(5y)-47.18%
ROIC(3y)N/A
ROIC(5y)N/A
CRMD Yearly ROA, ROE, ROICCRMD Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300 -400 -500

1.3 Margins

Looking at the Gross Margin, with a value of 92.66%, CRMD belongs to the top of the industry, outperforming 94.95% of the companies in the same industry.
CRMD's Gross Margin has improved in the last couple of years.
The Profit Margin and Operating Margin are not available for CRMD so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 92.66%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y63.88%
GM growth 5YN/A
CRMD Yearly Profit, Operating, Gross MarginsCRMD Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -10K -20K -30K -40K

More info and screens

7

2. Health

2.1 Basic Checks

CRMD does not have a ROIC to compare to the WACC, probably because it is not profitable.
CRMD has more shares outstanding than it did 1 year ago.
The number of shares outstanding for CRMD has been increased compared to 5 years ago.
There is no outstanding debt for CRMD. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
CRMD Yearly Shares OutstandingCRMD Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
CRMD Yearly Total Debt VS Total AssetsCRMD Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

CRMD has an Altman-Z score of 6.99. This indicates that CRMD is financially healthy and has little risk of bankruptcy at the moment.
CRMD has a better Altman-Z score (6.99) than 86.36% of its industry peers.
There is no outstanding debt for CRMD. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 6.99
ROIC/WACCN/A
WACC9.5%
CRMD Yearly LT Debt VS Equity VS FCFCRMD Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M -40M 60M 80M

2.3 Liquidity

A Current Ratio of 3.39 indicates that CRMD has no problem at all paying its short term obligations.
CRMD's Current ratio of 3.39 is in line compared to the rest of the industry. CRMD outperforms 58.59% of its industry peers.
A Quick Ratio of 3.16 indicates that CRMD has no problem at all paying its short term obligations.
CRMD has a Quick ratio (3.16) which is in line with its industry peers.
Industry RankSector Rank
Current Ratio 3.39
Quick Ratio 3.16
CRMD Yearly Current Assets VS Current LiabilitesCRMD Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

6

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 64.13% over the past year.
The Revenue has been growing by 174.29% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)64.13%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%184.62%
Revenue 1Y (TTM)N/A
Revenue growth 3Y511.63%
Revenue growth 5Y174.29%
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, CRMD will show a very strong growth in Earnings Per Share. The EPS will grow by 52.64% on average per year.
Based on estimates for the next years, CRMD will show a very strong growth in Revenue. The Revenue will grow by 48.61% on average per year.
EPS Next Y310.49%
EPS Next 2Y158.28%
EPS Next 3Y106.05%
EPS Next 5Y52.64%
Revenue Next Year231.47%
Revenue Next 2Y123.07%
Revenue Next 3Y87.99%
Revenue Next 5Y48.61%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
CRMD Yearly Revenue VS EstimatesCRMD Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 200M 400M 600M
CRMD Yearly EPS VS EstimatesCRMD Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 2 -2 4

More info and screens

4

4. Valuation

4.1 Price/Earnings Ratio

CRMD reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
A Price/Forward Earnings ratio of 13.23 indicates a correct valuation of CRMD.
CRMD's Price/Forward Earnings ratio is rather cheap when compared to the industry. CRMD is cheaper than 85.35% of the companies in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 21.20. CRMD is valued slightly cheaper when compared to this.
Industry RankSector Rank
PE N/A
Fwd PE 13.23
CRMD Price Earnings VS Forward Price EarningsCRMD Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20 -20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CRMD Per share dataCRMD EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as CRMD's earnings are expected to grow with 106.05% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y158.28%
EPS Next 3Y106.05%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for CRMD!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CORMEDIX INC

NASDAQ:CRMD (4/30/2025, 8:00:01 PM)

After market: 9.19 0 (0%)

9.19

+0.07 (+0.77%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)03-25 2025-03-25/bmo
Earnings (Next)05-08 2025-05-08/bmo
Inst Owners37.46%
Inst Owner Change-0.06%
Ins Owners1.84%
Ins Owner Change7.31%
Market Cap599.00M
Analysts83.33
Price Target15.81 (72.03%)
Short Float %13.66%
Short Ratio5.26
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)53.18%
Min EPS beat(2)52.29%
Max EPS beat(2)54.06%
EPS beat(4)4
Avg EPS beat(4)30%
Min EPS beat(4)1.96%
Max EPS beat(4)54.06%
EPS beat(8)5
Avg EPS beat(8)11.78%
EPS beat(12)8
Avg EPS beat(12)12.17%
EPS beat(16)10
Avg EPS beat(16)10.32%
Revenue beat(2)2
Avg Revenue beat(2)9.47%
Min Revenue beat(2)3.62%
Max Revenue beat(2)15.32%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-4.32%
PT rev (3m)-6.06%
EPS NQ rev (1m)37.02%
EPS NQ rev (3m)63.33%
EPS NY rev (1m)13.41%
EPS NY rev (3m)42.25%
Revenue NQ rev (1m)13.33%
Revenue NQ rev (3m)16.07%
Revenue NY rev (1m)0.87%
Revenue NY rev (3m)-0.8%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 13.23
P/S 13.78
P/FCF N/A
P/OCF N/A
P/B 7.08
P/tB 7.23
EV/EBITDA N/A
EPS(TTM)-0.33
EYN/A
EPS(NY)0.69
Fwd EY7.56%
FCF(TTM)-0.78
FCFYN/A
OCF(TTM)-0.78
OCFYN/A
SpS0.67
BVpS1.3
TBVpS1.27
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -15.09%
ROE -21.18%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 92.66%
FCFM N/A
ROA(3y)-39.81%
ROA(5y)-41%
ROE(3y)-47.06%
ROE(5y)-47.18%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y63.88%
GM growth 5YN/A
F-Score3
Asset Turnover0.37
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 37.35%
Cap/Sales 0.27%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.39
Quick Ratio 3.16
Altman-Z 6.99
F-Score3
WACC9.5%
ROIC/WACCN/A
Cap/Depr(3y)258.21%
Cap/Depr(5y)648.52%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)64.13%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%184.62%
EPS Next Y310.49%
EPS Next 2Y158.28%
EPS Next 3Y106.05%
EPS Next 5Y52.64%
Revenue 1Y (TTM)N/A
Revenue growth 3Y511.63%
Revenue growth 5Y174.29%
Sales Q2Q%N/A
Revenue Next Year231.47%
Revenue Next 2Y123.07%
Revenue Next 3Y87.99%
Revenue Next 5Y48.61%
EBIT growth 1Y54.34%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year305.31%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-30.96%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-31.78%
OCF growth 3YN/A
OCF growth 5YN/A